

UNITED STATED DEPARTMENT OF COMMERCE Unit of States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/508,913 03/16/00 UDEM 8 33.359-01F **EXAMINER** HM22/0605 AMERICAN HOME PRODUCTS CORPORATION WINKLER.H ONE CAMPUS DRIVE PAPER NUMBER ART UNIT PARSIPPANY NJ 07054 1648 DATE MAILED: 06/05/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

<u> </u>	Application No.	Applicant(s)
Office Action Summary	—	
	09/508,913	UDEM ET AL.
	Examiner	Art Unit
	Ulrike Winkler, Ph.D.	1648
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Peri d for Reply		
A SHORTENED STATUTORY PERIOD FOR REP	LY IS SET TO EXPIRE 1 MON	JTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a release if NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statu. - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	136 (a). In no event, however, may a repl ply within the statutory minimum of thirty (3 d will apply and will expire SIX (6) MONTH: tte, cause the application to become ABAN	y be timely filed 0) days will be considered timely. S from the mailing date of this communication. DONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on		
	This action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4)⊠ Claim(s) <u>1-11</u> is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)☐ Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims 1-11 are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are objected to by the Examiner.		
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. \$ 119		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. ≸ 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docume	nts have been received.	
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).		
Attachment(s)		
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper Note 	19) Notice of In	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)

Application/Control Number: 09/508,913

Art Unit: 1648

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-4, drawn to an attenuated respiratory syncytial virus subgroup B.

Group II, claims 5 and 6, drawn to a method of immunizing an individual to induce protection against RSV subgroup B.

Group III, claims 7 and 8 as the claims read on genome RSV, drawn to a transcription vector comprising and an isolated nucleic acid of RSV.

Group IV, claims 7 and 8 as the claims read on antigenome RSV, drawn to a transcription vector comprising and an isolated nucleic acid of RSV.

Group V, claims 9 and 10 as the claims read on genome RSV, drawn to a method of producing an infectious attenuated RSV subgroup B using a transcription vector.

Group VI, claims 9 and 10 as the claims read on antigenome RSV, drawn to a method of producing an infectious attenuated RSV using a transcription vector.

Group VII, claim 11, drawn to a nucleic acid molecule comprising an RSV subgroup B.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups I-VII appears a composition comprising an attenuated RSV subgroup B virus that contains a mutation in the polymerase L gene. Randolph et al. (EP 0 567 100 A1) discloses temperature sensitive, cold adapted RSV mutant viruses of subgroup A and B. Temperature sensitive, cold passage mutants were found to contain mutations in the polymerase gene (see Tolly et al. Vaccine 1996; Conners et al. 1995). Therefore, the technical feature linking the inventions of groups I-VII does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of group I is considered to be the attenuated RSV.

Application/Control Number: 09/508,913

Art Unit: 1648

The special technical feature of group II is considered to be a method of immunizing an individual to induce protection against RSV.

The special technical feature of group III is considered to be a genome RSV encoding transcription vector.

The special technical feature of group IV is considered to be an antigenome RSV encoding transcription vector.

The special technical feature of group V is considered to be a method of producing an infectious attenuated RSV using a genome RSV encoded transcription vector.

The special technical feature of group VI is considered to be a method of producing an infectious attenuated RSV using an antigenome RSV encoded transcription vector.

The special technical feature of group VII is considered an isolated nucleic acid comprising a RSV subgroup B in positive strand, antigenome RSV.

Accordingly, groups I-VII are not so linked by the same or corresponding technical feature as to form a single general inventive concept.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ulrike Winkler, Ph.D. whose telephone number is 703-308-8294. The examiner can normally be reached on 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Ulrike Winkler, Ph.D.

JEFFREY STUCKER
PRIMARY FYAMINER